Table 1 Sociodemographic and clinical characteristics of patients with advanced cancer in palliative care per evaluation period (before or during the COVID-19 pandemic); n = 673
Variables | Total n (%) | COVID-19 Pandemic | p-value | |
|---|---|---|---|---|
Before n = 204 (30.3%) | During n = 469 (69.7%) | |||
Age (years)a | ||||
< 60 | 277 (41.2%) | 80 (39.4%) | 197 (41.9%) | 0.544 |
≥ 60 | 396 (58.8%) | 123 (60.6%) | 273 (58.1%) | |
Sexa | ||||
Male | 281 (41.8%) | 83 (48.9%) | 198 (42.1%) | 0.764 |
Female | 392 (58.2%) | 120 (59.1%) | 272 (57.9%) | |
Skin colora | ||||
White | 262 (38.9%) | 61 (30.1%) | 201 (42.8%) | 0.002 |
Non-whiteb | 411 (61.1%) | 142 (69.9%) | 269 (57.2%) | |
Primary tumor sitea | ||||
Gastrointestinal tract | 148 (22.0%) | 31 (15.3%) | 117 (24.9%) | 0.008 |
Gynecological | 138 (20.5%) | 38 (18.7%) | 100 (21.3%) | |
Head and neckc | 106 (15.7%) | 35 (17.2%) | 71 (15.1%) | |
Breast | 82 (12.2%) | 31 (15.3%) | 51 (10.8%) | |
Lung | 62 (9.2%) | 21 (10.3%) | 41 (8.7%) | |
Skin, bone, and soft tissue | 70 (10.4%) | 17 (8.4%) | 53 (11.3%) | |
Othersd | 67 (10.0%) | 30 (14.8%) | 37 (7.9%) | |
Distant metastasisa | ||||
No | 108 (16.0%) | 39 (19.2%) | 69 (14.7%) | 0.142 |
Yes | 565 (84.0%) | 164 (80.8%) | 401 (85.3%) | |
Prior treatmenta | ||||
No | 108 (16.0%) | 35 (17.2%) | 73 (15.5%) | 0.579 |
Yes | 565 (84.0%) | 168 (82.8%) | 397 (84.5%) | |
Types of prior treatmenta | ||||
Surgery (yes) a | 307 (45.6%) | 93(45.8%) | 214 (45.5%) | 0.946 |
Chemotherapy (yes) a | 479 (71.2%) | 135(66.5%) | 344 (73.2%) | 0.079 |
Radiotherapy (yes)a | 345 (52.3%) | 90 (44.3%) | 255 (54.3%) | 0.018 |